Investigating the mechanisms of frontotemporal lobar degeneration using human samples and models
Official title: The TMEM106B-GRN-TDP43 triad: leveraging human samples and humanized models to unravel FTLD-TDP disease mechanisms
Funded at Flanders Interuniv Inst Biotechnology · NIH-10978733 · Data updated 2026-11-12
This study is looking at how certain proteins and genes affect frontotemporal lobar degeneration (FTLD), a type of dementia that impacts younger people, to help find better ways to diagnose and treat the condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Flanders Interuniv Inst Biotechnology NIH-funded |
| Lab location | 1 site (Gent, Belgium) |
| Project start | September 30, 2024 |
| Project end | August 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $538,380 |
| NIH project number | 1R01AG084672-01A1 |
| Project ID | NIH-10978733 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with frontotemporal lobar degeneration or those with a family history of the disease.
✕Less likely to help
Patients with other types of dementia or neurodegenerative disorders unrelated to FTLD may not benefit from this research.
What this research studies
This research focuses on frontotemporal lobar degeneration (FTLD), a type of dementia that affects personality and communication, often in individuals under 65. The study aims to understand the role of specific proteins, such as TDP-43 and progranulin, in the disease's progression by utilizing human samples and advanced humanized models. By examining genetic factors like the TMEM106B haplotype, the research seeks to uncover the underlying mechanisms of FTLD-TDP pathology, which could lead to better diagnostic and therapeutic strategies.
Why it matters
Potential benefit: If successful, this research could lead to improved understanding and treatment options for patients suffering from frontotemporal lobar degeneration.
How similar studies have gone: Previous research has shown promise in understanding neurodegenerative diseases through similar genetic and protein-focused approaches, indicating potential for success in this area.
Where this research is happening
-
Flanders Interuniv Inst Biotechnology
Gent, Belgium Active
Researchers
- Principal investigator: Rademakers, Rosa — Flanders Interuniv Inst Biotechnology
- Study coordinator: Rademakers, Rosa
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.